Infliximab

Summary

Infliximab (CHEMBL1201581) is an approved antibody (ATC L04AB02); indicated across 54 conditions including ankylosing spondylitis and crohn disease.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Antibody
• ATC class: L04AB02
• Indications: 54 conditions
• Clinical trials: 343

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1201581
Name	Infliximab
Type	Antibody
Max phase	4
ATC	L04AB02

Also known as: ABP 710, Abp-710, Avsola, Bow-015, BOW015, Ct p13, Ct-p-13, Ct-p13, CTP-13, CTP13, Flixabi, Infimab

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

54 indications (7 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
ankylosing spondylitis	4	MONDO:0005306	EFO:0003898
Crohn disease	4	MONDO:0005011	EFO:0000384
psoriasis	4	MONDO:0005083	EFO:0000676
rheumatoid arthritis	4	MONDO:0008383	EFO:0000685
ulcerative colitis	4	MONDO:0005101	EFO:0000729
psoriatic arthritis	4	MONDO:0011849	EFO:0003778
immune system disorder	4	MONDO:0005046	EFO:0000540
Kawasaki disease	3	MONDO:0012727	EFO:0004246
Behcet disease	3	MONDO:0007191	EFO:0003780
colitis	3	MONDO:0005292	EFO:0003872
graft versus host disease	3	MONDO:0013730	EFO:0004599
inflammatory bowel disease	3	MONDO:0005265	EFO:0003767
chronic obstructive pulmonary disease	3	MONDO:0005002	EFO:0000341
juvenile idiopathic arthritis	3	MONDO:0011429	EFO:0002609
chronic hepatitis C virus infection	3	MONDO:0005354	EFO:0004220
parapsoriasis	3	MONDO:0006592	EFO:1000747
polymyalgia rheumatica	3	MONDO:0019735	EFO:0008518
scleritis	3	MONDO:0001718	MONDO:0001718
lung neoplasm	3	MONDO:0021117	MONDO:0008903
severe acute respiratory syndrome	3	MONDO:0005091	MONDO:0100096
sarcoidosis	3	MONDO:0019338	MONDO:0019338
endometriosis	2	MONDO:0005133	EFO:0001065
hepatitis C virus infection	2	MONDO:0005231	EFO:0003047
eosinophilic esophagitis	2	MONDO:0005361	EFO:0004232
spondyloarthropathy	2	MONDO:0005095	EFO:0000706
hidradenitis suppurativa	2	MONDO:0006559	EFO:1000710
myelodysplastic syndrome	2	MONDO:0018881	EFO:0000198
dermatomyositis	2	MONDO:0016367	EFO:0000398
myositis disease	2	MONDO:0021167	EFO:0000783
ischemia reperfusion injury	2	MONDO:0005203	EFO:0002687
toxic epidermal necrolysis	2	MONDO:0019810	EFO:0004775
granulomatosis with polyangiitis	2	MONDO:0012105	EFO:0005297
reactive arthritis	2	MONDO:0017376	EFO:0007460
tropical spastic paraparesis	2	MONDO:0008039	EFO:0007527
microscopic polyangiitis	2	MONDO:0019124	EFO:1000784
temporal arteritis	2	MONDO:0008538	EFO:1001209
Takayasu arteritis	2	MONDO:0017991	EFO:1001857
Stevens-Johnson syndrome	2	MONDO:0018229	EFO:0004276
pemphigus	2	MONDO:0006594	EFO:1000749
metastatic melanoma	2	MONDO:0005191	EFO:0002617
type 1 diabetes mellitus	2	MONDO:0005147	MONDO:0005147
osteoarthritis	2	MONDO:0005178	MONDO:0005178
bipolar disorder	2	MONDO:0004985	MONDO:0004985
age-related macular degeneration	2	MONDO:0005150	EFO:0001365
polymyositis	2	MONDO:0019127	EFO:0003063
choroidal neovascularization	2	MONDO:0810000	MONDO:0810000
chronic beryllium disease	1	MONDO:0015274	EFO:0007168
chronic granulomatous disease	1	MONDO:0018305	MONDO:0018305
glaucoma	1	MONDO:0005041	MONDO:0005041

5 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 343.

Phase distribution

Phase	Trials
Not specified	101
PHASE3	85
PHASE4	82
PHASE2	44
PHASE1	16
PHASE1/PHASE2	8
PHASE2/PHASE3	6
EARLY_PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT04646187	PHASE4	ENROLLING_BY_INVITATION	De-escalation of Anti-TNF Therapy in Inflammatory Bowel Disease
NCT04835506	PHASE4	ACTIVE_NOT_RECRUITING	Proactive Infliximab Optimization Using a Pharmacokinetic Dashboard Versus Standard of Care in Patients With Inflammatory Bowel Disease: The OPTIMIZE Trial
NCT04999228	PHASE4	RECRUITING	Top Down Versus Step up in Pediatric Ulcerative Colitis
NCT05043870	PHASE4	RECRUITING	Combined Immunosuppression for Pediatric Crohn’s Disease
NCT05552287	PHASE4	RECRUITING	Pharmacokinetic Infliximab Data in Pediatric Crohn’s Disease
NCT05813860	PHASE4	NOT_YET_RECRUITING	HLADQA1*05 Genotype and the Efficacy of Treatment With Infliximab in Chinese Population Crohn’s Disease
NCT05823532	PHASE4	RECRUITING	Anti-Inflammatory Challenge in Schizophrenia
NCT05906576	PHASE4	RECRUITING	Post-marketing Registry Study of Infliximab for Injection in Chinese Pediatric Crohn’s Disease Patients
NCT06113913	PHASE4	RECRUITING	Subcutaneous Infliximab After A Previous Intravenous Dose Optimization
NCT07352566	PHASE4	NOT_YET_RECRUITING	Utilization of a Microdevice for Psoriasis and Atopic Dermatitis
NCT07415473	PHASE4	NOT_YET_RECRUITING	Akkermansia Muciniphila Combined With Infliximab for Promoting Intestinal Mucosal Healing in Crohn’s Disease
NCT07417696	PHASE4	NOT_YET_RECRUITING	Palmitoleic Acid Combined With Infliximab for Promoting Intestinal Mucosal Healing in Crohn’s Disease
NCT07510191	PHASE4	RECRUITING	TNFi Plus Low-Dose Upadacitinib vs TNFi Intensification in Crohn’s Disease With Suboptimal Response
NCT07550673	PHASE4	RECRUITING	Upadacitinib Versus Infliximab as Second-Line Treatment for Acute Severe Ulcerative Colitis（UPRISE）
NCT00133315	PHASE4	COMPLETED	TNFalfa Blocking Treatment of Spondylarthropathies
NCT00216177	PHASE4	UNKNOWN	Comparison of Adalimumab and Infliximab Treatment of Rheumatoid Arthritis
NCT00246064	PHASE4	COMPLETED	The Infliximab Rheumatoid Arthritis Methotrexate Tapering (iRAMT) Protocol
NCT00396747	PHASE4	COMPLETED	A Comparison of Methotrexate Alone or Combined to Infliximab or to Pulse Methylprednisolone in Early Rheumatoid Arthritis: A Magnetic Resonance Imaging Study
NCT00432406	PHASE4	COMPLETED	Tumor Necrosis Factors (TNF)-α Blockade for Psoriatic Arthritis
NCT00432432	PHASE4	COMPLETED	Combination Methotrexate and Infliximab
NCT00462072	PHASE4	COMPLETED	Centocor Microarray Study of Patients
NCT00463580	PHASE4	COMPLETED	A Study of Infliximab for Treatment Resistant Major Depression
NCT00507403	PHASE4	COMPLETED	Infliximab and Methotrexate in Ankylosing Spondylitis
NCT00554710	PHASE4	COMPLETED	Top Down Versus Step Up Strategies in Crohn’s Disease
NCT00574470	PHASE4	COMPLETED	Anti Cytokine Combination Therapy With Daclizumab and Infliximab for Treatment of Steroid Refractory Acute GVHD
NCT00589628	PHASE4	COMPLETED	Multi Center Prospective Registry of Infliximab Use for Childhood Uveitis
NCT00636142	PHASE4	COMPLETED	Effects of Infliximab on Insulin Sensitivity and Beta Cell Function in Insulin Resistant Human Obesity
NCT00686595	PHASE4	COMPLETED	A Study to Evaluate the Switch From Etanercept to Infliximab in Subjects With Moderate-to-Severe Psoriasis (Study P05133)
NCT00686894	PHASE4	TERMINATED	Enthesitis With Ultra Sonography Doppler in Spondyloarthropathies Treated With Infliximab (Study P04440)
NCT00688636	PHASE4	COMPLETED	Infliximab for the Prevention of Recurrent Crohn’s Disease After Surgery
NCT00714493	PHASE4	COMPLETED	RESTART C0168Z05 Rheumatoid Arthritis Study
NCT00752622	PHASE4	TERMINATED	Treatment With Infliximab in a Medical Setting (Study P05587)
NCT00778869	PHASE4	COMPLETED	Analysis of the Peripheral Blood Mononuclear Cells of Patients With Ankylosing Spondylitis During Infliximab Treatment (Study P04465)(COMPLETED)
NCT00779012	PHASE4	COMPLETED	A Study of the Efficacy and Tolerance of Remicade in the Treatment of Active Ankylosing Spondylitis (Study P04042)(COMPLETED)
NCT00779935	PHASE4	COMPLETED	Growth Factor Concentration to Predict an Ankylosing Spondylitis Patient’s Response to Infliximab (Study P04041)(COMPLETED)
NCT00794898	PHASE4	COMPLETED	Efficacy of Remicade in the Treatment of Active Rheumatoid Arthritis Despite Methotrexate (Study P03027)
NCT00896168	PHASE4	COMPLETED	An Efficacy and Safety Study of Infliximab in Participants With Rheumatoid Arthritis
NCT00908089	PHASE4	UNKNOWN	TNF-blocking Therapy in Combination With Disease-modifying Antirheumatic Drugs in Early Rheumatoid Arthritis
NCT00936143	PHASE4	COMPLETED	Efficacy and Safety Study of Infliximab (Remicade) to Treat Early Ankylosing Spondylitis
NCT01000441	PHASE4	COMPLETED	Rotation or Change of Biotherapy After First Anti-TNF Treatment Failure for Rheumatoid Arthritis

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).